Biotechnology

Kura Oncology

$35.60
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.56 (-1.62%) Today
+$1.51 (+4.43%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Kura Oncology and other stocks, options, and ETFs commission-free!

About KURA

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA. The listed name for KURA is Kura Oncology, Inc. Common Stock.

CEO
Troy E. Wilson
Employees
60
Headquarters
San Diego, California
Founded
2014
Market Cap
2.16B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
675.43K
High Today
$34.61
Low Today
$33.25
Open Price
$34.35
Volume
706.15K
52 Week High
$43.00
52 Week Low
$6.35

Collections

KURA Earnings

-$0.42
-$0.28
-$0.14
-$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Feb 23, Pre-Market

You May Also Like

RYI
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure